197 related articles for article (PubMed ID: 14580776)
21. Chromosomal abnormalities in Ph- cells of patients on imatinib.
McMullin MF; Humphreys M; Byrne J; Russell NH; Cuthbert RJ; O'Dwyer ME
Blood; 2003 Oct; 102(7):2700-1; author reply 2701. PubMed ID: 14504073
[No Abstract] [Full Text] [Related]
22. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
23. Simultaneous regression of Philadelphia chromosome and multiple nonrecurrent clonal chromosomal abnormalities with imatinib mesylate in a patient autografted 22 years before for chronic myelogenous leukemia.
Van Den Akker J; Coppo P; Portnoï MF; Barbu V; Bories D; Gorin NC
Leuk Lymphoma; 2007 Sep; 48(9):1858-65. PubMed ID: 17786726
[TBL] [Abstract][Full Text] [Related]
24. Clonal karyotypic abnormalities in Philadelphia negative cells of CML patients treated with imatinib: is it under-reported and does it have any clinical significance?
O'Shea D; Crotty G; Carroll P; Conneally E; McCann S; Neat MJ
Br J Haematol; 2004 Nov; 127(3):367-9. PubMed ID: 15491304
[No Abstract] [Full Text] [Related]
25. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Verstovsek S; Giles F; Rios MB; Shan J; Letvak L; Thomas D; Faderl S; Ferrajoli A; Cortes J
Blood; 2004 Apr; 103(8):2873-8. PubMed ID: 15070658
[TBL] [Abstract][Full Text] [Related]
26. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Jabbour E; Kantarjian HM; Abruzzo LV; O'Brien S; Garcia-Manero G; Verstovsek S; Shan J; Rios MB; Cortes J
Blood; 2007 Oct; 110(8):2991-5. PubMed ID: 17625066
[TBL] [Abstract][Full Text] [Related]
27. Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience.
Cojbasić I; Macukanović-Golubović L
Vojnosanit Pregl; 2010 Oct; 67(10):802-6. PubMed ID: 21061842
[TBL] [Abstract][Full Text] [Related]
28. The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate.
Feldman E; Najfeld V; Schuster M; Roboz G; Chadburn A; Silver RT
Exp Hematol; 2003 Aug; 31(8):702-7. PubMed ID: 12901975
[TBL] [Abstract][Full Text] [Related]
29. Chromosomal abnormalities in chronic myeloid leukemia: evidence of a hierarchy in imatinib treated cells.
Ostro D; Cheung K; Kamel-Reid S; Lipton JH
Leuk Lymphoma; 2007 May; 48(5):1029-31. PubMed ID: 17487749
[No Abstract] [Full Text] [Related]
30. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
[TBL] [Abstract][Full Text] [Related]
31. Imatinib mesylate in the treatment of chronic myelogenous leukemia.
Borthakur G; Cortes JE
Int J Hematol; 2004 Jun; 79(5):411-9. PubMed ID: 15239390
[TBL] [Abstract][Full Text] [Related]
32. [A new drug in the therapy of chronic myeloid leukemia: ST1571].
Salesi N; Bossone G; Della Longa G; Di Cocco B
Minerva Med; 2003 Apr; 94(2):71-6. PubMed ID: 12858155
[TBL] [Abstract][Full Text] [Related]
33. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
[TBL] [Abstract][Full Text] [Related]
34. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.
Bumm T; Müller C; Al-Ali HK; Krohn K; Shepherd P; Schmidt E; Leiblein S; Franke C; Hennig E; Friedrich T; Krahl R; Niederwieser D; Deininger MW
Blood; 2003 Mar; 101(5):1941-9. PubMed ID: 12411298
[TBL] [Abstract][Full Text] [Related]
35. Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case.
Mozziconacci MJ; Caillères S; Maurice C; Vey N; Sainty D; Blaise D; Lafage-Pochitaloff M
Leukemia; 2003 Sep; 17(9):1901-2. PubMed ID: 12970792
[No Abstract] [Full Text] [Related]
36. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.
O'Dwyer ME; Gatter KM; Loriaux M; Druker BJ; Olson SB; Magenis RE; Lawce H; Mauro MJ; Maziarz RT; Braziel RM
Leukemia; 2003 Mar; 17(3):481-7. PubMed ID: 12646934
[TBL] [Abstract][Full Text] [Related]
37. Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia.
Wang L; Zhu K; Zha X; Chen S; Yang L; Chen S; Li Y
J Hematol Oncol; 2010 Apr; 3():14. PubMed ID: 20377918
[TBL] [Abstract][Full Text] [Related]
38. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the cytogenetic and molecular analyses in the assessment of imatinib response in chronic myelocytic leukemia.
Palanduz S; Bayrak A; Sirma S; Vural B; Cefle K; Ucur A; Ozturk S; Yenerel MN; Besisik SK; Yavuz S; Diz-Kucukkaya R; Sargin D; Nalcaci M; Pekcelen Y; Ozbek U
Genet Test Mol Biomarkers; 2009 Oct; 13(5):599-602. PubMed ID: 19814615
[TBL] [Abstract][Full Text] [Related]
40. A chronic myeloid leukemia patient with atypical karyotype and BCR-ABL e13a3 transcript caused by complex chromosome rearrangement.
Masuko M; Furukawa T; Abe T; Wada R; Maruyama S; Kitajima T; Shibasaki Y; Toba K; Okada M; Aizawa Y
Int J Hematol; 2009 Sep; 90(2):230-234. PubMed ID: 19565180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]